Adherence to Anti-Retroviral Therapy and its determinants in HIV/AIDS patients: A review

Infectious Disorders - Drug Targets

Volumn 12, Issue 5, 2012, Pages 346-356

  Emamzadeh Fard, Sahra ^a,b   Fard, Sahar E ^c   SeyedAlinaghi, SeyedAhmad ^a   Paydary, Koosha ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Stevens Institute of Technology   (United States)

Author keywords

Adherence; Anti retroviral therapy; Correlations; HIV AIDS; Measurements

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; TENOFOVIR DISOPROXIL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AWARENESS; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; DIARRHEA; DRUG COST; DRUG DOSE REGIMEN; DRUG TREATMENT FAILURE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE HOMOSEXUAL; MEDICAL RECORD; MONOTHERAPY; MORTALITY; MOTIVATION; PATIENT COMPLIANCE; PATIENT EDUCATION; PILL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SELF REPORT; SOCIAL SUPPORT; SOCIOECONOMICS; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; TREATMENT FAILURE;

EID: 84872233557     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/187152612804142251     Document Type: Review

References (89)

1. Mills, E.J.; Nachega, J.B.; Buchan, I., Orbimski, J.; Attaran, A.; Singh, S.; Rachlis, B.; Wu, P.; Cooper, C.; Thabane, L.; Wilson, K.; Guyat, GH.; Bansberg, DR. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA, 2006, 296, 679-90.
2. Tyndall, M.W.; McNally, M.; Lai, C.; Zhang, R.; Wood, E.; Kerr, T.; Montaner, J.G. Directly observed therapy programmes for antiretroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes. Int J. Drug Policy,2007, 18, 281-7.
3. Gordillo, V.; del Amo, J.; Soriano, V.; González-Lahoz, J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS, 1999, 13,1763-9.
4. Fong, O.W., Ho, C.F., Fung, L.Y.; Lee, F.K.; Tse, W.H.; Yuen, C.Y.; Sin, K.P.; Wong, K.H. Determinants of adherence to highly active antiretroviral therapy in Chinese HIV/AIDS patients. HIV Med., 2003, 4, 133-8.
5. Wood, E.; Hogg, R.S.; Yip, B.; Harrigan, P.R.; O'Shaughnessy, M.V.; Montaner, J.S. Effect of medication adherence on survival of HIVinfected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann. Intern. Med., 2003, 139: 810-6.
6. Nieuwkerk, P.T.; Sprangers, M.A.; Burger, D.M.; Hoetelmans, R.M.; Hugen, P.W.; Danner, S.A.; van Der Ende, M.E.; Schneider, M.M.; Schrey, G.; Meenhorst, P.L.; Sprenger, H.G.; Kauffmann, R.H.; Jambroes, M.; Chesney, M.A.; de Wolf, F.; Lange, J.M. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch. Intern. Med., 2001, 161, 1962-8.
7. Bangsberg, D.R.; Charlebois, E.D.; Grant, R.M.; Holodniy, M.; Deeks, SG.; Perry, S. Conroy KN, Clark R, Guzman D, Zolopa A, Moss A. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS, 2003, 17, 1925-32.
8. Gonzalez, J.S.; Penedo, F.J.; Llabre, M.M.; Durán, R.E.; Antoni, M.H.; Schneiderman, N.; Horne, R. Physical symptoms, beliefs about medications, negative mood, and long-term HIV medication adherence. Ann. Behav. Med., 2007, 34, 46-55.
9. Pérez, J.; Pérez, D.; González, I.; Díaz-Jidy, M.; Orta, M.; Aragonés, C.; Joanes, J.; Santín, M.; Lantero, M.I.; Torres, R.; González, A.; Álvarez., A. Approaches to the Management of HIV/AIDS in Cuba. Geneva: World Health Organization; 2004.
10. Nabukeera-Barungi, N.; Kalyesubula, I.; Kekitiinwa, A.; Byakika-Tusiime, J.; Musoke, P. Adherence to antiretroviral therapy in children attending Mulago Hospital, Kampala. Ann. Trop. Paediatr., 2007, 27, 123-31.
11. Kerr, T.; Palepu, A.; Barness, G.; Walsh, J.; Hogg, R.; Montaner, J.; Tyndall, M.; Wood, E. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. Antivir. Ther., 2004, 9, 407-14.
12. Maggiolo, F.; Ravasio, L.; Ripamonti, D.; Gregis, G.; Quinzan, G.; Arici, C.; Airoldi, M.; Suter, F. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin. Infect. Dis., 2005, 40, 158-63.
13. Zorrilla, C.D.; Santiago, L.E.; Knubson, D.; Liberatore, K.; Estronza, G.; Colón, O.; Acevedo, M. Greater adherence to highly active antiretroviral therapy (HAART) between pregnant versus nonpregnant women living with HIV. Cell. Mol. Biol., 2003, 49, 1187-92.
14. Diabaté, S.; Alary, M.; Koffi, C.K. Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Côte d'Ivoire. AIDS, 2007, 21, 1799-803.
15. Garber, MC.; Nau, DP.; Erickson, SR.; Aikens, J.E.; Lawrence, J.B. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med. Care, 2004, 42, 649-52.
16. Berg, M.K.; Arnsten, H.J. Practical and conceptual challenges in measuring antiretroviral adherence. J. Acquir Immune Defic. Syndr., 2006, 43 (Suppl 1), S79-S87.
17. Stone, V.E.; Adelson-Mitty, J.; Duefield, C.A.; Steger, K.A.; Stein, M.D.; Mayer, K.H. Adherence to protease inhibitor (PI) therapy in clinical practice: usefulness of demographics, attitudes, and knowledge as predictors [abstract 32337]. In: Program and abstracts of the 12th World AIDS Conference (Geneva). Stockholm: International AIDS Society, 1998, 588.
18. Wagner, G.J.; Rabkin, J.G. Measuring medication adherence: are missed doses reported more accurately then perfect adherence? AIDS Care, 2000, 12, 405-8.
19. Stone, E.V. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin. Infec. Dis., 2001, 33, 865-72.
20. Orrell, C.; Bangsberg, D.R.; Badri, M.; Wood, R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS, 2003, 17, 1369-75.
21. Bell, D.J.; Kapitao, Y.; Sikwese, R.; van Ooserhout, J.J.; Lalloo, D.G. Adherence to antiretroviral therapy in patients receiving free treatment from a government hospital in Blantyre, Malawi. J. Acquir Immune Defic. Syndr., 2007, 45, 560-3.
22. Eholié, S.P.; Tanon, A.; Polneau, S.; Ouiminga, M.; Djadji, A.; Kangah-Koffi, C.; Diakité, N.; Anglaret, X.; Kakou, A.; Bissagnené, E. Field adherence to highly active antiretroviral therapy in HIV-infected adults in Abidjan, Côte d'Ivoire. J. Acquir Immune Defic. Syndr., 2007, 45: 355-8.
23. Bangsberg, D.R.; Hecht, F.M.; Charlebois, E.D.; Zolopa, A.R.; Holodniy, M.; Sheiner, L.; Bamberger, J.D.; Chesney, M.A.; Moss, A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 2000, 14, 357-66.
24. Farley, J.; Hines, S.; Musk, A.; Ferrus, S.; Tepper, V. Assessment of adherence to antiviral therapy in HIV-infected children using the Medication Event Monitoring System, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping. J. Acquir Immune Defic. Syndr., 2003, 33, 211-8.
25. Khalili, H.; Rohani, R.;Seyedalinaghi, S.A.; Hajiabdolbaghi, M.; Dashti-Khavidaki, S.; Hajhosssein Talasaz, A. Adherence to antiretroviral therapy among iranian HIV/AIDS patients. Current Clin. Pharmaco. l, 2012, 7, 1-5.
26. Hadadi, A.; Rasoulinejad, M.; Jamali, S.; SeyedAlinaghi, S.A.; Paydary, K.; Boyer, M.A.; Shojaie, E., Soleymani, A.; Faraji, S.; Kalantari, S.; Bayrami, S.; Hosseini, M. [Adherence to antiretroviral prophylaxis after occupational and non-occupational exposure to human immunodeficiency virus in patients consulting the Voluntary Counseling and Testing center of Imam Khomeini Hospital, Tehran, 2008-2009]. J. School Pub. Health Inst. Pub. Health Res., 2011, 9, 37-44.
27. Knowlton, R.A.; Yang, C.; Bohnert, A.;, Wissow, L.; Chander, G.; Arnsten, A.J. Informal care and reciprocity of support are associated with HAART adherence among Men in Baltimore, MD, USA. AIDS Behav. 2011, 15, 1429-1436.
28. Vriesendorp, R.; Cohen, A.; Kristanto, P.; Vrijens, B.; Rakesh, P.; Anand, B.; Uchechukwaka Iwebor, H.; Stiekema, J. Adherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in Botswana. Eur. J. Clin. Pharmacol., 2007, 63,1115-1121.
29. Bangsberg, R.D. Less than 95% adherence to Nonnucleoside Reverse-Transcriptase Inhibitor therapy can lead to viral suppression. Clin. Infec. Dis., 2006, 43,939-41.
30. Moss, R.A.; Hahn, A.J.; Perry, S.; Charlebois, D.E.; Guzman, D.; Clark, A.R.; Bangsberg, R.D. Adherence to highly active antiretroviral therapy in the homeless Population in San Francisco: a prospective study. Clin. Infec. Dis., 2004, 39,1190-8.
31. Sethi, K.A.; Celentano, D.D.; Gange, J.S.; Moore, D.R.; Gallant, E.J. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin. Infec. Dis., 2003, 37, 1112-8.
32. McNabb, J.; Ross, W.J.; Abriola, K.; Turley, C.; Nightingale, H.C.; Nicolau, P.D. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin. Infec. Dis., 2001, 33,700-5.
33. Acri, T.;TenHave, R.T.; Chapman, C.J.; Bogner, R.H.; Gross, R. Lack of association between retrospectively collected pharmacy refill data and electronic drug monitoring of antiretroviral adherence. AIDS Behav., 2010, 14, 748-754.
34. Parsons, T.J.; Rosof, E.; Mustanski, B. Medication adherence mediates the relationship between adherence self-efficacy and biological assessments of HIV health among those with alcohol use disorders. AIDS Behav., 2008, 12, 95-103.
35. Sorensen, L.J.; Haug, A.N.; Delucchi, L.K.; Gruber, V.; Kletter, E.; Batki, L.S.; Tulsky, P.J.; Barnett, P.; Hal, S. Voucher reinforcement improves medication adherence in HIV positive methadone patients: a randomized trial. Drug Alcohol Depend., 2007, 88, 54-63.
36. Beng, A.C.; Sánchez, L.; Campos, R.J.; Pérez, J. Antiretroviral therapy adherence in persons with HIV/AIDS in Cuba. MEDICC Review, 2011, 13, 17-23.
37. Schneider, J.; Kaplan, H.S.; Greenfield, S.; Li, W.; Wilson, B.I. Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. JGIM, 2004, 19, 1096-1103.
38. Sumari-de Boer, M.I.; Sprangers, G.A.M.; Prins, M.J.; Nieuwkerk, T.P. HIV stigma and depressive symptoms are related to adherence and virological response to antiretroviral treatment among immigrant and indigenous HIV infected patients. AIDS Behav., 2011.
39. Etard, O.F. J; Lanièce, I.; Fall, K.B.M.; Cilote, V.; Blazejewski, L.; Diop, K.; Desclaux, A.; Ecochard, R.; Ndoye, I.; Delaporte, E.; ANRS 1215-1290 Study Group. A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients. Trop. Med. and Inter. Health, 2007, 12, 1191-1198.
40. Fong, O.W.; Ho, C.F.; Fung, L.Y.; Lee, F.k.; Tse, W.H.; Yuen, C.Y.; Sin, K.P.; Wong, K.H. Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Medicine, 2003, 4, 133-138.
41. Fairley, C.K.; Permana, A.; Read, T.R. Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting. HIV Med., 2005, 6, 366-9.
42. Lehavot, K.; Huh, D.; Walters, L.K.; King, K.M.; Andrasik, M.P.; Simoni, J.M. Buffering effects of general and medication-specific social support on the association between substance use and HIV medication adherence. AIDS Patients Care and STDS, 2011, 25, 181-9.
43. Segeral, O.; Madec, Y.; Ban, B.; Ouk, V.; Hak, C.R.; Le Tiec, C.; Nerrienet, E.; Goujard, C.; Taburet, A.M.; Delfraissy, J.F.; Fontanet, A. Simplified assessment of antiretroviral adherence and prediction of virological efficacy in HIV-infected patients in Cambodia. AIDS Res. Treat., 2010, 1-10.
44. Ukwe, C.V.; Ekwunife, O.I.; Udeogaranya, O.P.; Iwuamadi, U.I. Self-reported adherence to HAART in South-Eastern Nigeria is related to patients' use of pill box. SAHARA J., 2010, 7, 10-5.
45. Ortego, C.; Huedo-Medina, T.B.; Vejo, J.; Llorca, F.J. Adherence to highly active antiretroviral therapy in Spain. A meta-analysis. Gac Sanit, 2011,25,282-9.
46. Shah, B.; Walshe, L.; Saple, D.G.; Mehta, S.H.; Ramnani, J.P.; Kharkar, R.D.; Bollinger, R.C.; Gupta, A. Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clin. Infec. Dis., 2007, 44, 1235-44.
47. Musiime, S.; Muhairwe, F.; Rutagengwa, A.; Mutimura, E.; Anastos, K.; Hoover, D.R.; Qiuhu, S.; Munyazesa, E.; Emile, I.; Uwineza, A.; Cowan, E. Adherence to highly active antiretroviral treatment in HIV-infected Rwandan women. PLoS One, 2011, 6, 1-6.
48. Ford, N.; Darder, M.; Spelman, T.; Maclean, E.; Mills, E.; Boulle, A. Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort. PLoS One., 2010, 5, 1-4.
49. Wohl, D.A.; Stephenson, B.L.; Golin, C.E.; Kiziah, C.N.; Rosen, D.; Ngo, B.; Liu, H.; Kaplan, A.H. Adherence to directly observed antiretroviral therapy among human immunodeficiency virusinfected prison inmates. Clin. Infec. Dis., 2003, 36, 1572-6.
50. Haberer, J.E.; Kahane, J.; Kigozi, I.; Emenyonu, N.; Hunt, P.; Martin, J.; Bangsberg, D.R. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav, 2010, 14,1340-6.
51. Martín, M.T.; del Cacho, E.; López, E.; Codina, C.; Tuset, M.; de Lazzari, E.; Miró, J.M.; Gatell, J.M.; Ribas, J. Adverse side effects of antiretroviral therapy: relationship between patients' perception and adherence. Med. Clin. (Barc.), 2007, 129, 127-33.
52. Spire, B.; Duran, S.; Souville, M.; Leport, C.; Raffi, F.; Moatti, J.P.; APROCO cohort study group. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc. Sci. Med., 2002, 54, 1481-96.
53. Riera, M.; La Fuente, Ld. L.; Castanyer, B.; Puigventós, F.; Villalonga, C.; Ribas, M.A.; Pareja, A.; Leyes, M.; Salas, A. Adherence to antiretroviral therapy measured by pill count and drug serum concentrations. Variables associated with a bad adherence. Med. Clin. (Barc), 2002, 119, 286-92.
54. Stone, V.E.; Jordan, J.; Tolson, J.; Miller, R.; Pilon, T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy regimens in predicting adherence. J. Acquir Immune Defic. Syndr.,2004, 36, 808-16.
55. Palepu, A.; Tyndall, M.W.; Chan, K.; Wood, E.; Montaner, J.S.; Hogg, R.S. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir. Ther.,2004, 9, 713-9.
56. Townsend, M.L.; Jackson, G.L.; Smith. R.;Wilson. K.H. Association between pharmacy medication refill-based adherence rates and cd4 count and viral-load responses: A retrospective analysis in treatment-experienced adults with HIV. Clin. Ther., 2007, 29, 711-6.
57. Halkitis, P.N.; Kutnick, A.H.; Rosof, E.; Slater, S. Parsons JT. Adherence to HIV medications in a cohort of men who have sex with men: impact of September 11th. J. Urban Health, 2003, 80, 161-6.
58. Horne, R.; Cooper, V.; Gellaitry, G.; Date, HL.; Fisher, M. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity concerns framework. J. Acquir Immune Defic. Syndr., 2007, 45, 334-41.
59. Tugenberg, T.; Ware, N.C.; Wyatt, M.A. Paradoxical effects of clinician emphasis on adherence to combination antiretroviral therapy for HIV/AIDS. AIDS Patient Care STDS, 2006, 20, 269-74.
60. Gross, R.; Zhang, Y.; Grossberg, R. Medication refill logistics and refill adherence in HIV. Pharmacoepidemiol. Drug Saf., 2005,14, 789-93.
61. Yuan, Y.; L'italien, G.; Mukherjee, J.; Iloeje, U.H. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med., 2006, 7, 156-62.
62. th inter-science conference on antimicrobial agents and chemotherapy (ICAAC) September 12-15, 2009 San Francisco, CA, USA. Poster# H-1572. Available from: http://www.hivandhepatitis.com/2009icr/icaac/pdfs/2_DeJesus.pdf. Accessed July 10, 2011.
63. Bangsberg, D.R.; Ragland, K.; Monk, A.; Deeks, S.G. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS, 2010, 24, 2835-40.
64. Lazo, M.; Gange, S.J.; Wilson, T.E.; Anastos, K.; Ostrow, D.G.; Witt, M.D.; Jacobson, L.P. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin. Infect. Dis., 2007, 45, 1377-85.
65. Ramadhani, H.O.; Thielman, N.M.; Landman, K.Z.; Ndosi, E.M.; Gao, F.; Kirchherr, J.L.; Shah, R; Shao, H.J.; Morpeth, S.C.; McNeill, J.D.; Shao, J.F.; Bartlett, J.A.; Crump, J.A. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin. Infect. Dis., 2007, 45, 1492-8.
66. Ammassari, A.; Trotta, M.P.; Murri, R.; Castelli, F.; Narciso, P.; Noto, P.; Vecchiet, J.; D'Arminio Monforte, A.; Wu, A.W.; Antinori, A.; AdICoNA Study Group. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J. Acquir Immune Defic. Syndr., 2002, 31, S123-S127.
67. Palepu, A.; Milloy, M.J.; Kerr, T.; Zhang, R.; Wood, E. Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. J. Urban Health, 2011, 88, 545-55.
68. Ekstrand, M.L.; Chandy, S.; Heylen, E.; Steward, W.; Singh, G. Developing useful HAART adherence measures for India: the Prerana study. J. Acquir Immune Defic. Syndr., 2010, 53, 415-416.
69. Bachhuber, M.; Bilker, W.B.; Wang, H.; Chapman, J.; Gross, R. Is antiretroviral therapy adherence substantially worse on weekends than weekdays?. J. Acquir Immune Defic. Syndr., 2010,54, 109-110.
70. Parashar, S.; Palmer, A.K.; O'Brien, N.; Chan, K.; Shen, A.; Coulter, S.; Montaner, J.S.G.; Hogg, R.S. Sticking to It: the effect of maximally assisted therapy on antiretroviral treatment adherence among individuals living with HIV who are unstably housed. AIDS Behav., 2011, 15,1612-1622.
71. Duong, M.; Piroth, L.; Peytavin, G.; Forte, F.; Kohli, E.; Grappin, M.; Buisson, M.; Chavanet, P.; Portier, H. Value of patient selfreport and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response. Clin. Infec. Dis., 2001, 33, 386-92.
72. Parienti, J.J.; Bangsberg, D.R.; Verdon, R.; Gardner, E.M. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin. Infec. Dis., 2009, 48, 484-8.
73. Petersen, M.L.; Wang, Y.; Laan, M.J.; Guzman, D.; Riley, E.; Bangsberg, D.R. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin. Infec. Dis., 2007, 45,908-15.
74. Mannheimer, Sh.; Friedland, G.; Matts, J.; Child, C.; Chesney, M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin. Infec. Dis., 2002, 34, 1115-21.
75. Inciardi, J.F.; Leeds, A.L. Assessing the utility of a community pharmacy refill record as a measure of adherence and viral load response in patients infected with human immunodeficiency virus. Pharmacotherapy, 2005, 25, 790-6.
76. Elise, A.; France, A.M.; Louise, W.M.; Bata, D.; François, R.; Roger, S.; Philippe, M. Assessment of adherence to highly active antiretroviral therapy in a cohort of African HIV-infected children in Abidjan, Côted'Ivoire. J. Acquir Immune Defic. Syndr., 2005, 40, 498-500.
77. Grossberg, R.; Zhang, Y.; Gross, R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J. Clin. Epidemiol., 2004, 57, 1107-10.
78. Simoni, J.M.; Montgomery, A.; Martin, E.; New, M.; Demas, P.A.; Rana, S. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics, 2007, 119, e1371-83.
79. Simoni, J.M.; Pantalone, D.W.; Plummer, M.D.; Huang, B. A randomized controlled trial of a peer support intervention targeting antiretroviral medication adherence and depressive symptomatology in HIV-positive men and women. Health Psychol., 2007, 26, 488-95.
80. Carrieri, M.P.; Raffi, F.; Lewden, C.; Sobel, A.; Michelet, C.; Cailleton, V.; Chêne, G.; Leport, C.; Moatti, J.P.; Spire, B.; APROCO study group. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir. Ther., 2003, 8, 585-94.
81. Sidat, M.; Fairley, C.; Grierson, J. Experiences and perceptions of patients with 100% adherence to highly active antiretroviral therapy: a qualitative study. AIDS Patient Care STDS, 2007, 21, 509-20.
82. Molina, J.M.; Perusat, S.; Ferchal, F. Once-daily combination therapy with emtricitabine, didanosine, and efaferenz in treatment näve HIVinfected adults: 64-week follow-up of the ANRS 091 trial [abstract 321]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 2001,138.
83. Maggiolo, F.; Migliorino, M.; Maserati, R. Once-a-day treatment for HIV infection: final 48 week results [abstract 320]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 2001,138.
84. Reynes, J.; Denisi, R.; Massip, P.; Izopet, J.; Pellegrin, I.; Segondy, M. Once-daily administration of didanosine in combination with stavudine in antiretroviral näve patients. J. Acquir Immune Defic. Syndr., 1999, 22,103-5.
85. Stenzel, M.; McKenzie, M.; Adelson-Mitty, J.; Flanigan, T. Modified directly observed therapy (MDOT) to enhance adherence to highly active antiretroviral therapy (HAART): 12 month follow-up [abstract ThPeB4992]. In: Program and abstracts of the 13th International Conference on AIDS (Durban, South Africa). Stockholm: International AIDS Society, 2000,312.
86. Sorensen, J.L.; Mascovich, A.; Wall, T.L.; DePhilippis, D.; Batki, S.L.; Chesney, M. Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care, 1998, 10,297-312.
87. Hader, S.L.; Weidle, P.J.; Cergnul, I.G. Directly observed antiretroviral therapy (DART) in residential treatment facilities in New York City [abstract 476]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 2001,185.
88. Fischl, M.; Castro, J.; Monroig, R. Impact of directly observed therapy on long-term outcomes in HIV clinical trials [abstract 528]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 2001, 202.
89. McDonald, H.P.; Garg, A.X.; Haynes, R.B. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA, 2002, 288, 2868-79.